Head and neck squamous cell carcinoma: Optimizing the therapeutic index

Expert Review of Anticancer Therapy

Volumn 5, Issue 3, 2005, Pages 501-514

  Rosenthal, David I ^a   Blanco, Angel I ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Altered fractionation; Amifostine; Chemoradiation; Head and neck cancer; Intensity modulated radiation therapy

Indexed keywords

AMIFOSTINE; BLEOMYCIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; KERATINOCYTE GROWTH FACTOR; PACLITAXEL; TAXANE DERIVATIVE;

AREA UNDER THE CURVE; ASTHENIA; BIOLOGICAL THERAPY; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; COST BENEFIT ANALYSIS; DISEASE EXACERBATION; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED DISEASE; DRUG INFUSION; DRUG TARGETING; DRUG TOLERABILITY; DYSPHAGIA; FIBROSIS; HEAD AND NECK CANCER; HEALTH CARE QUALITY; HUMAN; HYPOTENSION; INFUSION REACTION; INTENSITY MODULATED RADIATION THERAPY; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAUSEA; NONHUMAN; PATIENT SELECTION; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIATION INJURY; REVIEW; RISK BENEFIT ANALYSIS; SKIN MANIFESTATION; TARGET CELL DESTRUCTION; TREATMENT OUTCOME; TUMOR CELL; VOMITING; XEROSTOMIA;

AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM STAGING; PATIENT SELECTION; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY, CONFORMAL;

EID: 21244449988     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.5.3.501     Document Type: Review

References (104)

1. Rosenthal DI, Pistenmaa DA, Glatstein E. A review of neoadjuvant chemotherapy for head and neck cancer: partially shrunken tumors may be both leaner and meaner. Int. J. Radiat. Oncol. Biol. Phys. 28(1), 315-320 (1994).
2. Forastiere AA, Goepfert H, Maor M et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N. Engl. J. Med. 349(22), 2091-2098 (2003).
3. Eschwege F, Sancho-Garnier H, Gerard JP et al. Ten-year results of randomized trial comparing radiotherapy and concomitant bleomycin to radiotherapy alone in epidermoid carcinomas of the oropharynx: experience of the European Organization for Research and Treatment of Cancer. NCI Monogr. 6, 275-278 (1988).
4. Fu KK, Phillips TL, Silverberg IJ et al. Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group randomized trial. J. Clin. Oncol. 5(9), 1410-1418 (1987).
5. Lo TC, Wiley AL Jr, Ansfield FJ et al. Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized study. Am. J. Roentgenol. 126(2), 229-235 (1976).
6. Pfister DG, Ang K, Brockstein B et al. National Comprehensive Cancer Network (NCCN) practice guidelines for head and neck cancers. Oncology 14(11A), 163-194 (2000).
7. Forastiere AA, Trotti A. Radiotherapy and concurrent chemotherapy: a strategy that improves locoregional control and survival in oropharyngeal cancer. J. Natl Cancer Inst. 91(24), 2065-2066 (1999).
8. Bernier J, Domenge C, Ozsahin M et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 350, 1945-1952 (2004).
9. Cooper JS, Pajak TF, Forastiere AA et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous cell carcinoma of the head and neck. N. Engl. J. Med. 350, 1937-1944 (2004).
10. Ang KK. Altered fractionation trials in head and neck cancer. Semin. Radiat. Oncol. 8(4), 230-236 (1998).
11. Nguyen LN, Ang KK. Radiotherapy for cancer of the head and neck: altered fractionation regimens. Lancet Oncol. 3(11), 693-701 (2002).
12. Thames HD, Bentzen SM, Turesson I, Overgaard M, Van den Bogaert W. Time-dose factors in radiotherapy: a review of the human data. Radiother. Oncol. 19(3), 219-235 (1990).
13. Stuschke M, Thames HD. Hyperfractionated radiotherapy of human tumors: overview of the randomized clinical trials. Int. J. Radiat. Oncol. Biol. Phys. 37(2), 259-267 (1997).
14. Datta NR, Choudry AD, Gupta S, Bose AK. Twice a day versus once a day radiation therapy in head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 17(Suppl. 1), 132-133 (1989).
15. Pinto LH, Canary PC, Araujo CM, Bacelar SC, Souhami L. Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in Stages III and IV oropharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 21(3), 557-562 (1991).
16. Cummings B, O'Sullivan B, Keane T et al. 5-year results of 4 week/twice daily radiation schedule - the Toronto trial. 19th Annual Meeting of the European Society of Radiation Oncology (ESTRO). Proceedings of ESTRO. Radiother. Oncol. 56(Suppl. 1), S8 (2000).
17. Bourhis J, Audry H, Overgaard J et al. Meta-analysis of conventional versus altered fractionated radiotherapy in head and neck squamous cell carcinoma (HNSCC): final analyis. Int. J. Radiat. Oncol. Biol. Phys. (Suppl.) (2004).
18. Horiot JC, Le Fur R, N'Guyen T et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother. Oncol. 25(4), 231-241 (1992).
19. Dische S, Saunders M, Barrett A, Harvey A, Gibson D, Parmar M. A randomized multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother. Oncol. 44, 123-126 (1997).
20. Fu KK, Pajak TF, Trotti A et al. A Radiation Therapy Oncology Group (RTOG) Phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int. J. Radiat. Oncol. Biol. Phys. 48(1), 7-16 (2000).
21. Overgaard J, Hansen HS, Specht L et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 362(9388), 933-940 (2003).
22. Bourhis J, Lapeyre M, Rives M et al. Very accelerated radiotherapy in HNSCC: results of the GORTEC 94-02 randomized trial. Proc. Am. Soc. Clin. Oncol. (2000) (Abstract 1627).
23. Jackson SM, Weir LM, Hay JH, Tsang VH, Durham JS. A randomised trial of accelerated versus conventional radiotherapy in head and neck cancer. Radiother. Oncol., 43(1), 39-46 (1997).
24. Maciejewski B, Skladowski K, Pilecki B et al. Randomized clinical trial on accelerated 7 days per week fractionation in radiotherapy for head and neck cancer: preliminary report on acute toxicity. Radiother. Oncol. 40(2), 137-145 (1996).
25. Hsiung CY, Yorke ED, Chui CS et al. Intensity-modulated radiotherapy versus conventional 3D conformal radiotherapy for boost or salvage treatment of nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 53(3), 638-647 (2002).
26. Chui CS, Spirou SV. Inverse planning algorithms for external beam radiation therapy. Med. Dosim. 26(2), 189-197 (2001).
27. Rosenthal DI, Ang KK. Altered radiation therapy fractionation, chemoradiation, and patient selection for the treatment of head and neck squamous carcinoma. Semin. Radiat. Oncol. 14, 153-166 (2004).
28. Chao KSC, Wippold FJ, Ozyigit G et al. Determination and delineation of nodal target volumes for head and neck cancer based on the patterns of failure in patients receiving definitive and postoperative IMRT. Int. J. Radiat. Oncol. Biol. Phys. 53, 1174-1184 (2002).
29. Dale GRG. The application of the linear-quadratic dose-effect equation of fractionated and protracted radiotherapy. Cancer 75, 2351-2355 (1985).
30. Cheng JC, Chao KS, Low D. Comparison of intensity-modulated radiation therapy (IMRT) treatment techniques for nasopharyngeal carcinoma. Int. J. Cancer 96(2), 126-131 (2001).
31. Eisbruch A, Ship JA, Dawson LA et al. Salivary gland sparing and improved target irradiation by conformal and intensity-modulated irradiation of head and neck cancer. World J. Surg. 27(7), 832-837 (2003).
32. Lee N, Xia P, Quivey JM et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int. J. Radiat. Oncol. Biol. Phys. 53(1), 12-22 (2002).
33. Lee N, Xia P, Quivey JM et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int. J. Radiat. Oncol. Biol. Phys. 53(1), 12-22 (2002).
34. Chao KS, Ozyigit G, Blanco AI et al. Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume. Int. J. Radiat. Oncol. Biol. Phys. 59(1), 43-50 (2004).
35. Eisbruch A, Marsh LH, Dawson LA et al. Recurrences near base of skull after IMRT for head and neck cancer: implications for target delineation in high neck and for parotid gland sparing. Int. J. Radiat. Oncol. Biol. Phys. 59(1), 28-42 (2004).
36. Butler EB, Teh BS, Grant WH et al. Simultaneous Modulated Accelerated Radiation Therapy (SMART) boost: a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity-modulated radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 45(1), 21-32 (1999).
37. Amosson CM, Teh BS, Huang E et al. Accelerated fractionation for head and neck cancer using the Simultaneous Modulated Accelerated Radiation Therapy (SMART) boost technique. ASTRO (2001) (Abstract 1006).
38. Chao KSC, Low DA, Perez CA, et al. Intensity-modulated radiation therapy in head and neck cancers: the Mallinckrodt experience. Int. J. Cancer 90, 92-103 (2000).
39. Barendsen GW. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int. J. Radiat. Oncol. Biol. Phys. 8, 1981-1997 (1982).
40. Fowler JF. α, β and surviving fraction. Int. J. Radiat. Oncol. Biol. Phys. 24, 188-189 (1992).
41. Fowler JF, Harari PM, Leborgne F, Leborgne JH. Acute radiation reactions in oral and pharyngeal mucosa: tolerable levels in altered fractionation schedules. Radiother. Oncol. 69(2), 161-168 (2003).
42. Garden AS, Morrison WH, Wong P et al. Preliminary results of intensity-modulated radiation therapy for small primary oropharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 57(Suppl. 2), S407 (2003).
43. Mittal BB, Kepka A, Mahadevan A et al. Tissue/dose compensation to reduce toxicity from combined radiation and chemotherapy for advanced head and neck cancers. Int. J. Cancer 96(Suppl.), 61-70 (2001).
44. Hall EJ. Radiobiology for the Radiologist. Fifth Edition. Lippincott, Williams & Wilkins, PA, USA (2000).
45. Brizel DM, Wasserman TH, Henke M et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J. Clin. Oncol. 18, 3339-3345 (2000).
46. Antonadou D, Pepelassi M, Synodinou M et al. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 52, 739-747 (2002).
47. Koukourakis MI, Kyrias G, Kakolyris S et al. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized Phase II study. J. Clin. Oncol. 18, 2226-2233 (2000).
48. Schuchter LM, Hensley ML, Meropol NJ et al. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. 20, 2895-2903 (2002).
49. Hensley ML, Schuchter LM, Lindley C et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J. Clin. Oncol. 17, 3333-3355 (1999).
50. Hodson DI, Browman G, Thephamongkhol K et al. Role of amifostine as a radioprotectant in the management of patients with squamous cell head and neck cancer. Curr. Oncol. 10, 146-160 (2003).
51. Jacobs C, Makuch R. Efficacy of adjuvant chemotherapy for patients with resectable head and neck cancer: a subset analysis of the Head and Neck Contracts Program. J. Clin. Oncol. 8(5), 838-847 (1990).
52. Paccagnella A, Orlando A, Marchiori C et al. Phase III trial of initial chemotherapy in Stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J. Natl Cancer Inst. 86, 265-272 (1994).
53. Domenge C, Hill C, Lefebvre JL et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. Br. J. Cancer 83(12), 1594-1598 (2000).
54. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group: meta-analysis of chemotherapy on head and neck cancer. Lancet 355, 949-955 (2000).
55. Brizel DM, Albers ME, Fisher SR et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 338(25), 1798-1804 (1998).
56. Al-Sarraf M, LeBlanc M, Giri PG et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099. J. Clin. Oncol. 16, 1310-1317 (1998).
57. Al-Sarraf M. Treatment of locally advanced head and neck cancer: historical and critical review. Cancer Control 9(5), 387-399 (2002).
58. Ang KK, Harris J, Garden AS et al. Concomitant boost radiation and concurrent cisplatin for advanced head and neck carcinomas: preliminary results of a Phase II trial of the RTOG (99-14). Int. J. Radiat. Oncol. Biol. Phys. 54, 2-3 (2002).
59. Staar S, Rudat V, Stuetzer H et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy - results of a multicentric randomized German trial in advanced head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 50(5), 1161-1171 (2001).
60. Bernier J, Domenge C, Eschwege F et al. Chemo-radiotherapy as compared to radiotherapy alone, significantly increases disease-free and overall survival in head and neck cancer patients after surgery: results of EORTC Phase III trial 22931. Proceedings of the 43rd meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO). Int. J. Radiat. Oncol. Biol. Phys. 51(3), S1 (2001).
61. Calais G, Alfonsi M, Bardet E et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J. Natl. Cancer Inst. 91(24), 2081-2086 (1999).
62. Jeremic B, Shibamoto Y, Milicic B et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J. Clin. Oncol. 18(7), 1458-1464 (2000).
63. Wendt TG, Grabenbauer GG, Rodel CM et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J. Clin. Oncol. 16(4), 1318-1324 (1998).
64. Barkley HT, Fletcher GH, Jesse RH, Lindberg RD. Management of cervical lymph node metastases in squamous carcinomas of the tonsillar fossa, base of tongue, supraglottic larynx and hypopharynx. Am. J. Surg. 24, 462-467 (1972).
65. Kramer S, Gelber RD, Snow JB et al. Combined radiation therapy and surgery in the management of advanced head and neck cancer: final report of study 73-03 of the Radiation Therapy Oncology Group. Head Neck Surg. 10, 19-30 (1987).
66. Peters LJ, Goepfert H, Ang KK et al. Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 26, 3-11 (1993).
67. Ang KK, Trotti A, Brown BW et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 51, 571-578 (2001).
68. Bachaud JM, Cohen-Jonathan E, Alzieu C, David JM, Serrano E, Daly-Schveitzer N. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 36(5), 999-1004 (1996).
69. List MA, Bilar SP. Functional outcomes in head and neck cancer. Semin. Radiat. Oncol. 14(2), 178-189 (2004).
70. Robbins KT. Barriers to winning the battle with head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 53(1), 4-5 (2002).
71. Haselow RE, Warshaw MG, Oken MM et al. Radiation alone versus radiation with weekly low dose cis-platinum in unresectable cancer of the head and neck. Head Neck Cancer 2, 279-281 (1990).
72. Tsuchiya K, Nishioka T, Shirato H et al. A randomized trial of concomitant chemoradiotherapy for head and neck cancers: cisplatin (CDDP) versus carboplatin (CBDCA). Int. J. Radiat. Oncol. Biol. Phys. 51 (Suppl. 1), 337 (2001).
73. Jeremic B, Shibamoto Y, Stanisavljevic B et al. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial. Radiother. Oncol. 43, 29-37 (1997).
74. Abitbol AA, Sridhar KS, Lewin AA et al. Hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and mitomycin-c (+ granulocyte-colony stimulating factor) in the treatment of patients with locally advanced head and neck carcinoma. Cancer 80, 266-276 (1997).
75. Flood W, Lee DJ, Trotti A et al. Multimodality therapy of patients with locally advanced squamous cell cancer of the head and neck: preliminary results of two pilot trials using paclitaxel and cisplatin. Semin. Radiat. Oncol. 9(2 Suppl. 1), 64-69 (1999).
76. Machtay M, Rosenthal DI, Hershock D et al. Penn Cancer Center Clinical Trials Group: organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: a University of Pennsylvania Phase II Trial. J. Clin. Oncol. 20(19), 3964-3971 (2002).
77. Suntharalingam M. The role of concurrent chemotherapy and radiation in the management of patients with squamous cell carcinomas of die head and neck. Semin. Oncol. 30(4 Suppl. 9), 37-45 (2003).
78. Hershock D, Santiago R, Smith R et al. Weekly carboplatin and paclitaxel concurrent with radiation therapy (RT) for locally advanced head and neck squamous cell carcinoma (HNSCC): preliminary results from the Hospital of the University of Pennsylvania (HUP) experience. Proc. Am. Soc. Clin. Oncol. 21, 243a (2002).
79. Garden AS, Jasper JA, Morrison WH et al. Results of treatment of advanced AJCC stage, but early T-stage squamous cell carcinoma of the oropharynx: is systemic therapy required? Cancer (2004) (In Press).
80. Glisson BS, Murphy BA, Frenette G, Khuri FR, Forastiere AA. Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J. Clin. Oncol. 20(6), 1593-1599 (2002).
81. Glisson BS, Garden AS, Kies MS et al. Phase I study of docetaxel (D), cisplatin (P) and concomitant boost radiation for patients with locally advanced squamous cancer of the head and neck (SCHN). Proc. Am. Soc. Clin. Oncol. 21, 231a (2001)
82. Eisbruch A, Shewach DS, Bradford CR et al. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a Phase I trial and intracellular drug incorporation study. J. Clin. Oncol. 19(3), 792-799 (2001).
83. Bonner JA, Giralt J, Harari PM et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a Phase III study of high dose radiation therapy with or without cetuximab. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J. Clin. Oncol. 22(Suppl.), 5507 (2004).
84. Lydiatt WM, Schantz SP. Biological staging of head and neck cancer and its role in developing effective treatment strategies. Cancer Metastasis Rev. 15, 11-25 (1996).
85. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 92(4), 805-813 (2001).
86. Gillison ML, Shah KV. Human papillomavirus-associated head and neck squamous cell carcinoma: mounting evidence for an etiologic role for human papillomavirus in a subset of head and neck cancers. Curr. Opin. Oncol. 13(3), 183-188 (2001).
87. Shin DM, Donato NJ, Perez-Soler R et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin. Cancer Res. 7(5), 1204-1213 (2001).
88. Bonner JA, De Los Santos J, Waksal HW, Needle MN, Trummel HQ, Raisch KP. Epidermal growth factor receptor as a therapeutic target in head and neck cancer. Semin. Radiat. Oncol. 12(3 Suppl. 2), 11-20 (2002).
89. Ang KK, Berkey BA, Tu X et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 62, 7350-7356 (2002).
90. Harari PM, Huang SM. Combining EGFR inhibitors with radiation or chemotherapy: will preclinical studies predict clinical results? Int. J. Radiat. Oncol. Biol. Phys. 58, 976-983 (2004).
91. Harari PM, Huang SM. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int. J. Radiat. Oncol. Biol. Phys. 49, 427-433 (2001).
92. Hassan KA, Ang KK, El-Naggar AK et al. Cyclin B1 overexpression and resistance to radiotherapy in head and neck squamous cell carcinoma. Cancer Res. 62(22), 6414-6417 (2002).
93. Bonner JA, Giralt J, Harari PM et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of the head and neck: a Phase II study of high dose radiation therapy with or withour cetuximab. J. Clin. Oncol. 22(14S), 5507 (2004).
94. Friedlander PL. The use of genetic markers in the clinical care of patients with head and neck cancer. Arch. Otolaryngol. Head Neck Surg. 129(3) 363-366 (2003).
95. Koch WM. Clinical implications of biomarkers in head and neck cancer. Curr. Oncol. Rep. 1(2), 129-137 (1999).
96. Sidransky D. Emerging molecular markers of cancer. Nature Rev. Cancer 2(3), 210-219 (2002).
97. Raben D, Bianco C, Milas L et al. Targeted therapies and radiation for the treatment of head and neck cancer: are we making progress? Semin. Radiat. Oncol. 14, 139-152 (2004).
98. AngKK, Berkey BA, Tu X et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 62, 7350-7356 (2002).
99. Ang KK, Andratschke NH, Milas L. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int. J. Radiat. Oncol. Biol. Phys. 58, 959-965 (2004).
100. Brizel DM, Dodge RK, Clough RW et al. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother. Oncol. 53, 113-117 (1999).
101. Hassan KA, Ang KK, EI-Naggar AK et al. Cyclin B1 overexpression and resistance to radiotherapy in head and neck squamous cell carcinoma. Cancer Res. 62, 6414-6417 (2002).
102. Milas L, Mason KA, Ang KK. Epidermal growth factor receptor and its inhibition in radiotherapy: in vivo findings. Int. J. Radiat. Biol. 79, 539-545 (2003).
103. Nakata E, Hunter N, Mason K et al. C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 59, 1163-1173 (2004).
104. Prosnitz RG, Yao B, Farrell CL et al. Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 61, 1087-1095 (2005).